Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 15;119(14):2645-53.
doi: 10.1002/cncr.28111. Epub 2013 Apr 26.

Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience

Sarah E S Leary  1 , Amy W Wozniak, Catherine A Billups, Jianrong Wu, Valerie McPherson, Michael D Neel, Bhaskar N Rao, Najat C Daw
Affiliations

Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience

Sarah E S Leary et al. Cancer. .

Abstract

Background: Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear.

Methods: We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test.

Results: The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS (P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS (P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS (P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1).

Conclusions: Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents.

Keywords: chemotherapy; osteosarcoma; outcome; prognostic factors; relapse; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of relapse, number of complete remission (CR), and life status of all 110 patients with relapsed osteosarcoma. *Five patients were long-term survivors in CR3, but one patient died of a cerebral aneurysm 18 years after diagnosis of osteosarcoma.
Figure 2
Figure 2
Median time from complete remission to subsequent relapse according to number of relapse in patients with relapsed osteosarcoma.
Figure 3
Figure 3
Post-relapse survival (PRS) and event-free survival (PREFS) for all 110 patients with relapsed osteosarcoma.
Figure 4
Figure 4
Post-relapse survival (PRS) distributions according to time to first relapse (A) and ability to achieve second complete remission (B) for all 110 patients with relapsed osteosarcoma, and according to laterality of relapse for patients with lung relapse only who achieved second complete remission (CR2) (C). Post-relapse event-free survival (PREFS) distributions according to chemotherapy use at first relapse for patients with relapsed osteosarcoma who did not achieve CR2 (D).
See this image and copyright information in PMC

References

    1. Bacci G, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41(18):2836–45. - PubMed
    1. Longhi A, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423–36. - PubMed
    1. Meyer WH, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children’s Research Hospital OS-91 trial. J Clin Oncol. 2001;19(1):171–82. - PubMed
    1. Bacci G, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44(7):748–55. - PubMed
    1. Chou AJ, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2005;104(10):2214–21. - PubMed

Publication types

MeSH terms